KRT-232 and TKI Study in Chronic Myeloid Leukemia

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI). This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML (CML-CP) and accelerated phase (CML-AP) who have failed TKI treatments.

Additional locations may be listed on ClinicalTrials.gov for NCT04835584.

Trial PhasePhase I/II

Trial Typetreatment

Lead OrganizationKartos Therapeutics, Inc.

• Primary IDKRT-232-117
• Secondary IDsNCI-2021-12575
• ClinicalTrials.gov IDNCT04835584